ClinicalTrials.gg
CompletedNCT04039607CheckMate 9DWUpdated Aug 25, 2026

A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma

A Phase 3 interventional study of Nivolumab and Ipilimumab in Hepatocellular Carcinoma, sponsored by Bristol-Myers Squibb. Completed at 210 sites in 26 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-25.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
732
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 53 studies testing nivolumab in Carcinoma, Hepatocellular — 11 open to participants now, 17 under way, 1 of them phase 3. Nivolumab · Carcinoma, Hepatocellular.

Enrollment
4th of 53
732 · median 40
Started
2019
with 12 others
Phase 3
4 of 53
none open now
Registered
25th of 53
by date
Lead sponsor
5 of 53
Bristol-Myers Squibb

Among the 53 studies testing nivolumab in Carcinoma, Hepatocellular, this one is the 4th largest by enrollment, is one of 13 that started in 2019, is one of 4 in phase 3, and was the 25th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,062 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

11 of the 53 studies testing nivolumab in Carcinoma, Hepatocellular are open now, in 4 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 737 Carcinoma, Hepatocellular studies recruiting now, 382 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing nivolumab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

The main purpose of this study is to compare the overall survival (OS) of nivolumab plus ipilimumab versus standard of care (SOC) (sorafenib or lenvatinib) in all randomized participants with advanced hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

03

Conditions studied

  • Hepatocellular Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have a diagnosis of HCC based on histological confirmation
  • Participants must have an advanced HCC
  • Participants must have at least one (RECIST) 1.1 measurable previously untreated lesion
  • score 5 or 6
  • (ECOG) performance status(PS) 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
  • Prior liver transplant
  • Episodes of hepatic encephalopathy (greater than or equal to [>=] Grade 2) within 12 months prior to randomization
  • Active or

Other protocol-defined inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
732 participants (actual)

Study arms

  • Experimental
    Nivolumab + Ipilimumab

    Drug: Nivolumab · Drug: Ipilimumab

  • Active comparator
    Sorafenib/lenvatinib

    Drug: Sorafenib · Drug: lenvatinib

Interventions

  • Participants will receive nivolumab as intravenous (IV) infusion.

  • Participants will receive ipilimumab as IV infusion.

  • Participants will receive sorafenib as oral tablets.

  • Participants will receive lenvatinib as oral capsules.

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Time frame: Up to 4 years

Secondary outcomes

  1. Objective Response Rate (ORR)

    Time frame: Up to 4 years

  2. Duration of Response (DOR)

    Time frame: Up to 4 years

  3. Time to Symptom Deterioration (TTSD)

    Time frame: Up to 4 years

07

Study locations

210 sites
  • Local Institution - 0292
    Tucson, Arizona 85719, United States
  • Local Institution - 0288
    Coronado, California 92118, United States
  • Local Institution - 0157
    Duarte, California 91010-3012, United States
  • Local Institution - 0077
    Washington D.C., District of Columbia 20007, United States
  • Local Institution - 0027
    Louisville, Kentucky 40217, United States
  • Local Institution - 0190
    Baltimore, Maryland 21287, United States
  • Local Institution
    Ann Arbor, Michigan 48105, United States
  • Local Institution - 0018
    Detroit, Michigan 48202, United States
  • Local Institution - 0295
    Newark, New Jersey 07103, United States
  • Local Institution - 0043
    Toledo, Ohio 43623, United States
  • Local Institution - 0284
    Pittsburgh, Pennsylvania 15212, United States
  • Local Institution - 0304
    Dallas, Texas 75203, United States
  • Local Institution - 0202
    Houston, Texas 77030, United States
  • Local Institution - 0046
    Lubbock, Texas 79410, United States
  • Local Institution - 0172
    Salt Lake City, Utah 84106, United States
  • Local Institution - 0037
    Caba, Buenos Aires C1090AAS, Argentina
  • Local Institution - 0194
    Pilar, Buenos Aires B1629ODT, Argentina
  • Local Institution - 0282
    Rosario, Santa Fe Province 2000, Argentina
  • Local Institution - 0136
    Buenos Aires, C1426ANZ, Argentina
  • Local Institution - 0058
    San Miguel de Tucumán, 4000, Argentina
  • Local Institution - 0003
    Kogarah, New South Wales 2217, Australia
  • Local Institution - 0038
    Liverpool, New South Wales 1871, Australia
  • Local Institution - 0002
    Westmead, New South Wales 2145, Australia
  • Local Institution - 0004
    Birtinya, Queensland 4560, Australia
  • Local Institution - 0013
    Herston, Queensland 4029, Australia
  • Local Institution - 0009
    Adelaide, South Australia 5000, Australia
  • Local Institution - 0019
    Clayton, Victoria 3168, Australia
  • Local Institution - 0026
    Fitzroy, Victoria 3065, Australia
  • Local Institution - 0001
    Melbourne, Victoria 3004, Australia
  • Local Institution - 0020
    St Albans, Victoria 3021, Australia
  • Local Institution - 0114
    Sankt Pölten, Lower Austria 3100, Austria
  • Local Institution - 0057
    Wiener Neustadt, Lower Austria 2700, Austria
  • Local Institution - 0188
    Graz, 8036, Austria
  • Local Institution - 0065
    Klagenfurt, 9020, Austria
  • Local Institution - 0186
    Vienna, 1090, Austria
  • Local Institution - 0034
    Brussels, 1070, Belgium
  • Local Institution - 0008
    Federal District, 72115700, Belgium
  • Local Institution - 0124
    Ghent, 9000, Belgium
  • Local Institution - 0298
    Ghent, 9000, Belgium
  • Local Institution - 0099
    Haine-Saint-Paul, 7100, Belgium
  • Local Institution - 0064
    Leuven, 3000, Belgium
  • Local Institution - 0104
    Liège, 4000, Belgium
  • Local Institution - 0278
    Vitória, Espírito Santo 29055-450, Brazil
  • Local Institution
    Salvador, Estado de Bahia 41253190, Brazil
  • Local Institution - 0061
    Salvador, Estado de Bahia 41950-640, Brazil
  • Local Institution - 0181
    Brasília, Federal District 70200-730, Brazil
  • Local Institution - 0279
    Ijuí, Rio Grande do Sul 98700-000, Brazil
  • Local Institution - 0060
    Pelotas, Rio Grande do Sul 96020-360, Brazil
  • Local Institution - 0054
    Jaú, São Paulo 17210-120, Brazil
  • Hospital de Base de Sao Jose do Rio Preto
    São José do Rio Preto, São Paulo 15090-000, Brazil
  • Local Institution - 0016
    Paranã, 81520-060, Brazil
  • Local Institution - 0015
    Rio de Janeiro, 22793-080, Brazil
  • Local Institution - 0023
    São Paulo, 01246-000, Brazil
  • Local Institution - 0022
    São Paulo, 01323-900, Brazil
  • Local Institution - 0050
    São Paulo, 04038-034, Brazil
  • Local Institution - 0192
    Edmonton, Alberta T6G 1Z2, Canada
  • Local Institution - 0296
    Temuco, Araucania 4780000, Chile
  • Local Institution - 0094
    La Serena, Coquimbo Region 1720430, Chile
  • Local Institution - 0283
    Santiago, RM 7630372, Chile
  • Local Institution - 0095
    Santiago, Santiago Metropolitan 0, Chile
  • Local Institution - 0024
    Santiago, Santiago Metropolitan 7710007, Chile
  • Local Institution - 0156
    Santiago, Santiago Metropolitan 8380456, Chile
  • Local Institution - 0012
    Viña del Mar, Valparaiso 2520598, Chile
  • Local Institution - 0216
    Viña del Mar, Valparaiso 2540402, Chile
  • Local Institution - 0120
    Hefei, Anhui 230022, China
  • Local Institution - 0146
    Hefei, Anhui 230601, China
  • Local Institution - 0175
    Beijing, Beijing Municipality 100000, China
  • Local Institution - 0152
    Beijing, Beijing Municipality 100142, China
  • Local Institution - 0151
    Fuzhou, Fujian 350002, China
  • Local Institution - 0121
    Fuzhou, Fujian 350014, China
  • Local Institution - 0125
    Guangzhou, Guangdong 510000, China
  • Local Institution - 0150
    Guangzhou, Guangdong 510515, China
  • Local Institution - 0135
    Harbin, Heilongjiang 150081, China
  • Local Institution - 0109
    Changsha, Hunan 410006, China
  • Local Institution - 0059
    Changsha, Hunan 410011, China
  • Local Institution - 0130
    Nanjing, Jiangsu 210002, China
  • Local Institution - 0145
    Nanchang, Jiangxi 330006, China
  • Local Institution - 0149
    Nanchang, Jiangxi 330019, China
  • Local Institution - 0162
    Changchun, Jilin 130021, China
  • Local Institution - 0166
    Changchun, Jilin 130102, China
  • Local Institution - 0131
    Dalian, Liaoning 116023, China
  • Local Institution - 0123
    Shenyang, Liaoning 110004, China
  • Local Institution - 0132
    Shenyang, Liaoning 110117, China
  • Local Institution - 0133
    Xi'an, Shaanxi 710038, China
  • Local Institution - 0147
    Xi'an, Shan3xi 710061, China
  • Local Institution - 0307
    Xi'an, Shan3xi 710100, China
  • Local Institution - 0153
    Qingdao, Shandong 266000, China
  • Local Institution - 0134
    Shanghai, Shanghai Municipality 200032, China
  • Local Institution - 0179
    Chongqing, Sichuan 400030, China
  • Local Institution - 0108
    Hangzhou, Zhejiang 310000, China
  • Local Institution - 0107
    Hangzhou, Zhejiang 310022, China
  • Local Institution - 0274
    Prague, Prague 14059, Czechia
  • Local Institution
    Brno, 60200, Czechia
  • Local Institution - 0068
    Amiens, 80054, France
  • Local Institution - 0116
    Caen, 14033, France
  • Local Institution - 0069
    Clichy, 92110, France
  • Local Institution - 0138
    Dijon, 21000, France
  • Local Institution - 0081
    Grenoble, 38043, France
  • Local Institution - 0070
    Lyon, 69004, France
  • Local Institution
    Marseille, 13009, France

Showing the first 100 of 210 sites across 26 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Yau T, Galle PR, Decaens T, Sangro B, Qin S, da Fonseca LG, Karachiwala H, Blanc JF, Park JW, Gane E, Pinter M, Matilla Pena A, Ikeda M, Tai D, Santoro A, Pizarro G, Chiu CF, Schenker M, He A, Chon HJ, Wojcik-Tomaszewska J, Verset G, Wang QQ, Stromko C, Neely J, Singh P, Jimenez Exposito MJ, Kudo M. A plain language summary of the CheckMate 9DW study: nivolumab in combination with ipilimumab for unresectable hepatocellular carcinoma (advanced liver cancer). Future Oncol. 2026 Apr;22(10):1135-1152. doi: 10.1080/14796694.2026.2651375. Epub 2026 Apr 14. PubMed 41981891 ↗
  • Yau T, Galle PR, Decaens T, Sangro B, Qin S, da Fonseca LG, Karachiwala H, Blanc JF, Park JW, Gane E, Pinter M, Pena AM, Ikeda M, Tai D, Santoro A, Pizarro G, Chiu CF, Schenker M, He A, Chon HJ, Wojcik-Tomaszewska J, Verset G, Wang QQ, Stromko C, Neely J, Singh P, Jimenez Exposito MJ, Kudo M; CheckMate 9DW investigators. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial. Lancet. 2025 May 24;405(10492):1851-1864. doi: 10.1016/S0140-6736(25)00403-9. Epub 2025 May 8. PubMed 40349714 ↗
  • Huynh JC, Cho M, Monjazeb A, Al-Obeidi E, Singh A, Tam K, Lara F, Martinez A, Garcia L, Kim EJ. Phase I/II trial of BMS-986,205 and nivolumab as first line therapy in hepatocellular carcinoma. Invest New Drugs. 2024 Feb;42(1):35-43. doi: 10.1007/s10637-023-01416-w. Epub 2023 Dec 1. PubMed 38038862 ↗

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2019 to primary completion in Jul 2026, 81 months.

Of 52 industry-sponsored phase 3 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 63. This study's 81 months is above that.

Counting every sponsor, half of 138 studies reached it within 56 months; a quarter within 43 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2019
First posted
Jul 31, 2019
StartActual
Sep 30, 2019
Primary completionActual
Jul 9, 2026
CompletionActual
Jul 9, 2026
Last update
Aug 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04039607
Responsible party
Sponsor
First posted
Jul 31, 2019
Start date
Sep 30, 2019
Primary completion
Jul 9, 2026
Completion
Jul 9, 2026
Last update
Aug 25, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Ipilimumab

Start the discussion